$EKSO
EKSO BIONICS HOLDINGS, INC.

2020 Q4 Form 10-K Financial Statement

#000154908421000012 Filed on February 25, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019
Revenue $2.250M $3.720M $13.92M
YoY Change -39.52% 12.73% 22.81%
Cost Of Revenue $890.0K $1.870M $7.153M
YoY Change -52.41% 3.31% 1.85%
Gross Profit $1.360M $1.860M $6.764M
YoY Change -26.88% 24.83% 56.97%
Gross Profit Margin 60.44% 50.0% 48.6%
Selling, General & Admin $3.650M $4.110M $18.81M
YoY Change -11.19% -22.31% -26.22%
% of Gross Profit 268.38% 220.97% 278.05%
Research & Development $710.0K $560.0K $4.596M
YoY Change 26.79% -59.12% -21.4%
% of Gross Profit 52.21% 30.11% 67.95%
Depreciation & Amortization $150.0K $170.0K $690.0K
YoY Change -11.76% -51.43% -31.62%
% of Gross Profit 11.03% 9.14% 10.2%
Operating Expenses $4.360M $4.690M $23.40M
YoY Change -7.04% -29.26% -25.32%
Operating Profit -$3.000M -$2.830M -$16.64M
YoY Change 6.01% -44.94% -38.44%
Interest Expense -$30.00K -$70.00K $384.0K
YoY Change -57.14% -46.15% -36.0%
% of Operating Profit
Other Income/Expense, Net -$950.0K $190.0K $4.507M
YoY Change -600.0% -83.33% 11760.53%
Pretax Income -$3.980M -$2.720M -$10.32M
YoY Change 46.32% -34.14% -58.36%
Income Tax
% Of Pretax Income
Net Earnings -$3.980M -$2.720M -$12.13M
YoY Change 46.32% -34.14% -55.05%
Net Earnings / Revenue -176.89% -73.12% -87.17%
Basic Earnings Per Share -$2.53
Diluted Earnings Per Share -$477.2K -$531.3K -$2.53
COMMON SHARES
Basic Shares Outstanding 8.316M shares 74.95M shares 4.794M shares
Diluted Shares Outstanding 4.794M shares

Balance Sheet

Concept 2020 Q4 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.86M $10.87M $10.87M
YoY Change 18.31% 41.91% 41.91%
Cash & Equivalents $12.86M $10.87M
Short-Term Investments
Other Short-Term Assets $190.0K $240.0K $240.0K
YoY Change -20.83% -14.29% -14.29%
Inventory $1.978M $2.489M $2.490M
Prepaid Expenses
Receivables $3.224M $5.208M $5.210M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.42M $18.81M $18.81M
YoY Change -2.06% 25.66% 25.65%
LONG-TERM ASSETS
Property, Plant & Equipment $1.172M $1.657M $2.740M
YoY Change -29.27% -29.94% 15.61%
Goodwill $0.00 $189.0K
YoY Change -100.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $178.0K $180.0K
YoY Change 79.78% 32.84% 38.46%
Total Long-Term Assets $2.177M $3.108M $3.110M
YoY Change -29.95% 15.63% 15.61%
TOTAL ASSETS
Total Short-Term Assets $18.42M $18.81M $18.81M
Total Long-Term Assets $2.177M $3.108M $3.110M
Total Assets $20.60M $21.92M $21.92M
YoY Change -6.01% 24.13% 24.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.501M $1.903M $1.900M
YoY Change -21.12% -39.7% -39.87%
Accrued Expenses $1.429M $1.683M $2.010M
YoY Change -15.09% -51.76% -31.4%
Deferred Revenue $1.496M $1.492M
YoY Change 0.27% 35.39%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.333M $2.350M
YoY Change -100.0% 0.0% -0.84%
Total Short-Term Liabilities $4.974M $7.832M $7.830M
YoY Change -36.49% -22.3% -22.32%
LONG-TERM LIABILITIES
Long-Term Debt $1.989M $407.0K $410.0K
YoY Change 388.7% -84.63% -84.53%
Other Long-Term Liabilities $38.00K $72.00K $6.880M
YoY Change -47.22% -39.5% 212.73%
Total Long-Term Liabilities $2.027M $479.0K $7.290M
YoY Change 323.17% -82.69% 50.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.974M $7.832M $7.830M
Total Long-Term Liabilities $2.027M $479.0K $7.290M
Total Liabilities $16.16M $15.12M $15.12M
YoY Change 6.91% 1.28% 1.27%
SHAREHOLDERS EQUITY
Retained Earnings -$199.1M -$183.3M
YoY Change 8.63% 7.09%
Common Stock $8.000K $6.000K
YoY Change 33.33% -90.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.434M $6.797M $6.800M
YoY Change
Total Liabilities & Shareholders Equity $20.60M $21.92M $21.92M
YoY Change -6.01% 24.13% 24.12%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$3.980M -$2.720M -$12.13M
YoY Change 46.32% -34.14% -55.05%
Depreciation, Depletion And Amortization $150.0K $170.0K $690.0K
YoY Change -11.76% -51.43% -31.62%
Cash From Operating Activities -$1.740M -$1.490M -$15.77M
YoY Change 16.78% -71.12% -28.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $60.00K
YoY Change -100.0% -54.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$60.00K
YoY Change -100.0% -54.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $21.19M
YoY Change 376.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.270M $19.04M
YoY Change -100.0% -3981.82% 737.62%
NET CHANGE
Cash From Operating Activities -1.740M -1.490M -$15.77M
Cash From Investing Activities 0.000 0.000 -$60.00K
Cash From Financing Activities 0.000 4.270M $19.04M
Net Change In Cash -1.740M 2.780M $3.217M
YoY Change -162.59% -151.96% -115.96%
FREE CASH FLOW
Cash From Operating Activities -$1.740M -$1.490M -$15.77M
Capital Expenditures $0.00 $0.00 $60.00K
Free Cash Flow -$1.740M -$1.490M -$15.83M
YoY Change 16.78% -70.67% -28.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001549084
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0667
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0667
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37854
CY2020 dei Entity Registrant Name
EntityRegistrantName
Ekso Bionics Holdings, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0367049
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
1414 Harbour Way South
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1201
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Richmond
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94804
CY2020 dei City Area Code
CityAreaCode
510
CY2020 dei Local Phone Number
LocalPhoneNumber
984-1761
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020 dei Trading Symbol
TradingSymbol
EKSO
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
52257307 USD
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12599900 shares
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12862000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10872000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
121000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3389000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5208000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
2489000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
191000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
238000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18420000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
18807000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1657000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
685000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1084000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
0 USD
CY2019Q4 us-gaap Goodwill
Goodwill
189000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
178000 USD
CY2020Q4 us-gaap Assets
Assets
20597000 USD
CY2019Q4 us-gaap Assets
Assets
21915000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1501000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1903000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1683000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1492000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2333000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
548000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
421000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4974000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7832000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1789000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3075000 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
407000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
233000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
711000 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6037000 USD
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
4307000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
72000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
16163000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
15118000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8349000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8349000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5795000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5795000 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
204376000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190019000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-847000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
50000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199103000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183278000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6797000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21915000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13917000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3812000 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7153000 USD
CY2020 us-gaap Gross Profit
GrossProfit
5070000 USD
CY2019 us-gaap Gross Profit
GrossProfit
6764000 USD
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7752000 USD
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11398000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2474000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4596000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7702000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7409000 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020 us-gaap Restructuring Charges
RestructuringCharges
244000 USD
CY2019 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
18361000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
23403000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-13291000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-16639000 USD
CY2020 us-gaap Interest Expense
InterestExpense
139000 USD
CY2019 us-gaap Interest Expense
InterestExpense
384000 USD
CY2020 ekso Warrant Issuance Expense
WarrantIssuanceExpense
329000 USD
CY2019 ekso Warrant Issuance Expense
WarrantIssuanceExpense
1096000 USD
CY2020 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-3056000 USD
CY2019 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
6376000 USD
CY2020 ekso Gain Loss On Warrant Modification
GainLossOnWarrantModification
0 USD
CY2019 ekso Gain Loss On Warrant Modification
GainLossOnWarrantModification
-257000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
990000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-132000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2534000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4507000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15825000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-12132000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-897000 USD
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
142000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16722000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11990000 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.21
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.53
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7164000 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4794000 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2728000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-12132000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12444000 USD
CY2019 ekso Stock Issued During Period Value Equiposis Sales Earn Outs
StockIssuedDuringPeriodValueEquiposisSalesEarnOuts
22000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
228000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
191000 USD
CY2019 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
919000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2255000 USD
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
142000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6797000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15825000 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7082000 USD
CY2020 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
7310000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
155000 USD
CY2020 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
50000 USD
CY2020 ekso Adjustments To Additional Paid In Capital Warrant Issuance
AdjustmentsToAdditionalPaidInCapitalWarrantIssuance
2322000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2084000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-897000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15825000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-12132000 USD
CY2020 us-gaap Depreciation
Depreciation
620000 USD
CY2019 us-gaap Depreciation
Depreciation
690000 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
65000 USD
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
52000 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
28000 USD
CY2019 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
64000 USD
CY2020 ekso Gain Loss On Modification Of Operating Lease Liabilities
GainLossOnModificationOfOperatingLeaseLiabilities
-38000 USD
CY2019 ekso Gain Loss On Modification Of Operating Lease Liabilities
GainLossOnModificationOfOperatingLeaseLiabilities
0 USD
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-66000 USD
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 USD
CY2020 ekso Common Stock Contribution
CommonStockContribution
169000 USD
CY2019 ekso Common Stock Contribution
CommonStockContribution
142000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2410000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2255000 USD
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
329000 USD
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1096000 USD
CY2020 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-3056000 USD
CY2019 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
6376000 USD
CY2020 ekso Gain Loss On Warrant Modification
GainLossOnWarrantModification
0 USD
CY2019 ekso Gain Loss On Warrant Modification
GainLossOnWarrantModification
-257000 USD
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
947000 USD
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-133000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1754000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1599000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-379000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-959000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-247000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-369000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-402000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1231000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-876000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1135000 USD
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21000 USD
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
684000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8755000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15772000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7082000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21188000 USD
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1278000 USD
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2377000 USD
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1512000 USD
CY2019 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
228000 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3334000 USD
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3078000 USD
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10704000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19039000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1990000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3217000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10872000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7655000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12862000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10872000 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
109000 USD
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
309000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
6000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
23000 USD
CY2020 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3976000 USD
CY2019 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
0 USD
CY2020 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
155000 USD
CY2019 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
191000 USD
CY2020 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
-132000 USD
CY2019 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
77000 USD
CY2020 us-gaap Stock Issued1
StockIssued1
50000 USD
CY2019 us-gaap Stock Issued1
StockIssued1
919000 USD
CY2020 ekso Operating Leases Right Of Use Asset Initial Recognition
OperatingLeasesRightOfUseAssetInitialRecognition
0 USD
CY2019 ekso Operating Leases Right Of Use Asset Initial Recognition
OperatingLeasesRightOfUseAssetInitialRecognition
1454000 USD
CY2020 ekso Operating Leases Liability Initial Recognition
OperatingLeasesLiabilityInitialRecognition
0 USD
CY2019 ekso Operating Leases Liability Initial Recognition
OperatingLeasesLiabilityInitialRecognition
1498000 USD
CY2020 ekso Restricted Stock Issued
RestrictedStockIssued
0 USD
CY2019 ekso Restricted Stock Issued
RestrictedStockIssued
63000 USD
CY2020 ekso Operating Leases Increase Decrease In Deferred Rent
OperatingLeasesIncreaseDecreaseInDeferredRent
0 USD
CY2019 ekso Operating Leases Increase Decrease In Deferred Rent
OperatingLeasesIncreaseDecreaseInDeferredRent
44000 USD
CY2020 ekso Sales Earnout
SalesEarnout
0 USD
CY2019 ekso Sales Earnout
SalesEarnout
22000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199103000 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3334000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8755000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12862000 USD
CY2020 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.35
CY2020Q4 ekso Debt Covenant Covenant Compliance Unrestricted Cash
DebtCovenantCovenantComplianceUnrestrictedCash
2000000 USD
CY2020 ekso Unrestricted Cash
UnrestrictedCash
10862000 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18000 USD
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.  The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2020 and 2019. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div>
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1724000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2208000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
29000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
236000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
252000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
2489000 USD
CY2020Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.35
CY2020 us-gaap Restructuring Charges
RestructuringCharges
244000 USD
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 USD
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 USD
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
189000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
189000 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
0 USD
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1496000 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7164000 shares
CY2019Q1 us-gaap Grants Receivable
GrantsReceivable
1500000 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12132000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15825000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15825000 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12132000 USD
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4794000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7164000 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4794000 shares
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.53
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.21
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.53
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1997000 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1761000 shares
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-66000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1492000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2020Q4 ekso Deferred Extended Maintenance And Support
DeferredExtendedMaintenanceAndSupport
2902000 USD
CY2019Q4 ekso Deferred Extended Maintenance And Support
DeferredExtendedMaintenanceAndSupport
2837000 USD
CY2020Q4 ekso Deferred Royalties
DeferredRoyalties
282000 USD
CY2019Q4 ekso Deferred Royalties
DeferredRoyalties
290000 USD
CY2020Q4 ekso Deferred Device Revenue
DeferredDeviceRevenue
118000 USD
CY2019Q4 ekso Deferred Device Revenue
DeferredDeviceRevenue
154000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3281000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1789000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3281000 USD
CY2020 ekso Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
1922000 USD
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1901000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
690000 USD
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
908000 USD
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
898000 USD
CY2020Q4 ekso Contractwith Customer Liability Non Cancellable Backlog
ContractwithCustomerLiabilityNonCancellableBacklog
515000 USD
CY2020Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3389000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5208000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13917000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5829000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5883000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4657000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4226000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1657000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
620000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1194000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1098000 USD
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
188000 USD
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
285000 USD
CY2020Q4 ekso Accrued Clinical Cost Current
AccruedClinicalCostCurrent
47000 USD
CY2019Q4 ekso Accrued Clinical Cost Current
AccruedClinicalCostCurrent
300000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12862000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
836000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
55000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
781000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
599000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
237000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1683000 USD
CY2020 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa, and one or two years in the Asia Pacific region.
CY2020 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0849
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1512000 USD
CY2020Q4 ekso Long Term Debt Maturities Repayments Of Principal Remainder To Two Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear
0 USD
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2000000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2000000 USD
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
11000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
1989000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1989000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
1989000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
548000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
233000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
781000 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
537000 USD
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
551000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M8D
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
169000 USD
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
142000 USD
CY2020 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
45000 USD
CY2019Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.00
CY2019Q3 ekso Number Of Consecutive Business Days
NumberOfConsecutiveBusinessDays
30 days
CY2019Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.00
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8349000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8349000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1178000 shares
CY2020 ekso Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
996000 shares
CY2020 ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
126000 shares
CY2020 ekso Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
723000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1325000 shares
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
141000 shares
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
137000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
111000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
67000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
293000 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
233000 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
333000 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
800000 shares
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
529000 shares
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
31.62
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
342000 shares
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
40.63
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0144
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0165
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0167
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.02
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.03
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2410000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2255000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14954000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10321000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-871000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1811000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15825000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12132000 USD
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.044
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.006
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.009
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.166
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.272
CY2020 ekso Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant
EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant
-0.045
CY2019 ekso Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant
EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant
0.087
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
235000 USD
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
263000 USD
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
220000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2547000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2197000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43241000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40683000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1837000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1817000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
380000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
289000 USD
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
401000 USD
CY2020Q4 ekso Deferred Tax Assets Operating Lease Right Of Use Asset
DeferredTaxAssetsOperatingLeaseRightOfUseAsset
110000 USD
CY2019Q4 ekso Deferred Tax Assets Operating Lease Right Of Use Asset
DeferredTaxAssetsOperatingLeaseRightOfUseAsset
224000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
37000 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
45000 USD
CY2020Q4 ekso Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
88000 USD
CY2019Q4 ekso Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
214000 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3899000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
27000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
43000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48673000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45481000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3192000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
637000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
645000 USD
CY2020Q4 ekso Number Of License Agreements
NumberOfLicenseAgreements
2 license_agreement
CY2020Q4 us-gaap Purchase Obligation
PurchaseObligation
396000 USD
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
4192000 USD
CY2020Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
689000 USD
CY2020Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
3503000 USD
CY2020Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
0 USD
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3812000 USD
CY2020 us-gaap Gross Profit
GrossProfit
5070000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13917000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13917000 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7153000 USD
CY2019 us-gaap Gross Profit
GrossProfit
6764000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD

Files In Submission

Name View Source Status
0001549084-21-000012-index-headers.html Edgar Link pending
0001549084-21-000012-index.html Edgar Link pending
0001549084-21-000012.txt Edgar Link pending
0001549084-21-000012-xbrl.zip Edgar Link pending
ekso-20201231.htm Edgar Link pending
ekso-20201231.xsd Edgar Link pending
ekso-20201231_cal.xml Edgar Link unprocessable
ekso-20201231_def.xml Edgar Link unprocessable
ekso-20201231_htm.xml Edgar Link completed
ekso-20201231_lab.xml Edgar Link unprocessable
ekso-20201231_pre.xml Edgar Link unprocessable
exhibit1030.htm Edgar Link pending
exhibit21112312020.htm Edgar Link pending
exhibit23112312020.htm Edgar Link pending
exhibit31112312020.htm Edgar Link pending
exhibit31212312020.htm Edgar Link pending
exhibit32112312020.htm Edgar Link pending
exhibit32212312020.htm Edgar Link pending
exhibit410.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending